STOCK TITAN
  1. Home
  2. News
  3. OBIO

Orchestra BioMed Holdings Inc - OBIO STOCK NEWS

IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
fda approval
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
fda approval
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
management
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
conferences
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
HAE : NYSE OBIO : Nasdaq
Vivasure Medical Announces FDA IDE Approval to Initiate U.S. Pivotal Study
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed to Present at Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
OBIO : Nasdaq
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
conferences
Stock OBIO logo
Orchestra BioMed Holdings Inc
Nasdaq:OBIO

OBIO Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing